Noopept: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 14 sources cited
Overview
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, GVS-111) is a synthetic dipeptide-derived nootropic developed in Russia that is estimated to be 1,000 times more potent than piracetam by weight. It enhances memory, learning, and neuroprotection through BDNF and NGF upregulation, AMPA receptor modulation, and antioxidant effects. It is one of the most widely used and well-studied nootropic compounds globally.
Mechanism of Action
Noopept is rapidly metabolized to cyclo-prolylglycine, its active metabolite, which acts as a positive modulator of AMPA receptors, with its anxiolytic and neuroprotective effects in animals depending on AMPA and Trk receptor activation. It increases BDNF and NGF mRNA in the rat hippocampus, while in the cerebral cortex a single dose lowered them, and the hippocampal effect did not fade over 28 days of treatment. Additionally, Noopept has antioxidant properties, reducing lipid peroxidation and scavenging reactive oxygen species in neuronal tissue. It also modulates acetylcholine signaling, improving cholinergic neurotransmission. Unlike piracetam, Noopept has an additional anxiolytic component, likely through modulation of inhibitory GABA circuits.
Noopept Benefits: What the Research Shows
- Ostrovskaya et al. (2014) in the Journal of Biomedical Science showed Noopept protected PC12 cells from amyloid-beta(25-35) toxicity, reducing apoptosis, reactive oxygen species and tau phosphorylation
- Russian clinical studies compared Noopept with piracetam in patients with mild cognitive impairment of vascular and traumatic origin, and an open study in 60 stroke patients reported better MMSE and verbal fluency scores after two months
- Ostrovskaya et al. (2008) in Bulletin of Experimental Biology and Medicine found NGF and BDNF mRNA rose in the rat hippocampus after Noopept, with the effect holding up over 28 days of treatment
- Preclinical studies show Noopept has a selective anxiolytic action in rodents on top of its memory effects, and strengthens inhibitory synaptic transmission in rat hippocampal slices
- Gudasheva and colleagues designed Noopept as a dipeptide analog of piracetam, an approach reviewed in Current Pharmaceutical Design (2018)
- A study in Bulletin of Experimental Biology and Medicine showed Noopept prevented scopolamine-induced loss of spatial memory in BALB/c mice
Noopept Dosage
- Oral: 10 mg two or three times daily; published Russian studies used 20 mg a day, and the tablets are 5 mg and 10 mg
- Sublingual: 10–20 mg under the tongue for faster absorption and higher bioavailability
- Intranasal: 5–10 mg for rapid onset cognitive effects
- Start at 10 mg twice daily and increase based on response
- Take with a fat source for improved oral absorption
- Cycle: the published Russian studies ran courses of about two months
- Effects are noticeable within 30–60 minutes orally; near-immediate sublingually
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Noopept Side Effects & Safety
Known Side Effects
- Headache — the most commonly reported side effect, often attributed to increased cholinergic demand; may be mitigated by supplementing with a choline source (alpha-GPC)
- Irritability — reported at higher doses, likely related to excessive glutamatergic stimulation
- Insomnia — if dosed too late in the day
- Brain fog paradox — some users report worsened cognition at doses exceeding 30 mg, suggesting a U-shaped dose-response curve
- GI discomfort — mild nausea or stomach upset, usually with oral dosing on an empty stomach
Safety Profile
Noopept has been through formal clinical trials in Russia and is approved there as a nootropic medication (Noopept tablets, 10 mg). Published trials report few adverse events at the doses used, though they were small and short, and it is not approved for human use in the United States. Dependence and withdrawal have not been studied, and 28 days of treatment in rats produced no tolerance in its neurotrophic effect. No acute toxicity figure for Noopept was found in the published literature, though its effective dose is about a thousandth of piracetam's. Caution is advised in individuals with hypertension, as some reports suggest mild blood pressure elevation. It should not be combined with other potent glutamate modulators without caution. Pregnancy and breastfeeding are contraindications due to lack of safety data.
What to Expect
Within 30–60 minutes: Subtle increase in mental clarity and focus. Colors may appear slightly more vivid. Verbal fluency improves. Days 1–3: Cognitive enhancement becomes more consistent. Improved ability to concentrate on demanding tasks, better recall of recently learned information. Week 1–2: Cumulative neurotrophin effects emerge — memory consolidation improves, learning new material feels easier. Many users report improved dream recall. Weeks 3–8: Peak nootropic effects. Users describe enhanced mental stamina, improved problem-solving, and greater capacity for sustained intellectual work. After cessation, benefits persist for 3–7 days before gradually fading.
Common Stacks
N-Acetyl Semax Amidate
NASA upregulates BDNF through melanocortin pathways while Noopept enhances it through glutamatergic mechanisms — complementary neurotrophic support
NA-Selank Amidate
Selank's anxiolytic effects pair well with Noopept's cognitive enhancement, reducing the risk of overstimulation while maintaining nootropic benefits
PE-22-28
PE-22-28 promotes neurogenesis and cognitive function, complementing Noopept's synaptic plasticity enhancement
Storage & Handling
Store Noopept tablets or powder at room temperature (15–25°C) in a cool, dry place away from light and moisture. Noopept is relatively stable in solid form with a shelf life of 2–3 years. Solutions for intranasal use should be refrigerated and used within 4 weeks. No special reconstitution needed for oral or sublingual use. Sublingual powder should be kept in an airtight container.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. 2009.
- Amelin AV, Iliukhina AIu, Shmonin AA. Noopept in the treatment of mild cognitive impairment in patients with stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2011.
- Ostrovskaya RU, Gudasheva TA, Zaplina AP, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med. 2008.
- Ostrovskaya RU, Vakhitova YV, Kuzmina USh, et al. Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci. 2014.
- Ostrovskaya RU, Gruden MA, Bobkova NA, et al. The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. J Psychopharmacol. 2007.
- Pelsman A, Hoyo-Vadillo C, Gudasheva TA, et al. GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons. Int J Dev Neurosci. 2003.
- Boyko SS, Zherdev VP, Shevchenko RV. Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats. Biomed Khim. 2018.
- Gudasheva TA, Povarnina PY, Koliasnikova KN, et al. The Anxiolytic Effect of the Neuropeptide Cycloprolylglycine Is Mediated by AMPA and TrkB Receptors. Dokl Biochem Biophys. 2020.
- Povarov IS, Kondratenko RV, Derevyagin VI, et al. Nootropic dipeptide noopept enhances inhibitory synaptic transmission in the hippocampus. Bull Exp Biol Med. 2015.
- Kondratenko RV, Povarov IS, Kolbaev SN, et al. Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat. Neurosci Lett. 2022.
- Belnik AP, Ostrovskaya RU, Poletaeva II. Dipeptide preparation Noopept prevents scopolamine-induced deficit of spatial memory in BALB/c mice. Bull Exp Biol Med. 2007.
- Ostrovskaia RU, Gudasheva TA, Voronina TA, et al. The original novel nootropic and neuroprotective agent noopept. Eksp Klin Farmakol. 2002.
- Gudasheva TA, Ostrovskaya RU, Seredenin SB. Novel Technologies for Dipeptide Drugs Design and their Implantation. Curr Pharm Des. 2018.
- Cohen PA, Avula B, Wang YH, et al. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. Neurol Clin Pract. 2021.
Related Peptides
Track Noopept in Your Protocol
Log your Noopept doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free